(c) 2024 PillSync.com

dextroamphetamine saccharate amphetamine aspartate monohydrate dextroamphetamine sulfate amphetamine sulfate er capsule

1 INDICATIONS AND USAGE Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release, a CNS stimulant, is indicated for the treatment of attention deficit hyperactivity disorder (ADHD). ( 1 ) Children (ages 6 to 12): Efficacy was established in one 3-week outpatient, controlled trial and one analogue classroom, controlled trial in children with ADHD. ( 14 ) Adolescents (ages 13 to 17): Efficacy was established in one 4-week controlled trial in adolescents with ADHD. ( 14 ) Adults: Efficacy was established in one 4-week controlled trial in adults with ADHD. ( 14 ) 1.1 attention deficit hyperactivity disorder Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release is indicated for the treatment of attention deficit hyperactivity disorder (ADHD). The efficacy of Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release in the treatment of ADHD was established on the basis of two controlled trials in children aged 6 to 12, one controlled trial in adolescents aged 13 to 17, and one controlled trial in adults who met DSM-IV Ā® criteria for ADHD [see Clinical Studies ( 14 )]. A diagnosis of ADHD (DSM-IV Ā® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; "on the go;" excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presence of the required number of DSM-IV Ā® characteristics. Need for Comprehensive Treatment Program Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the child's symptoms. Long-Term Use The effectiveness of Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release for long-term use, i.e., for more than 3 weeks in children and 4 weeks in adolescents and adults, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

par pharmaceutical, inc.


4 years ago CAPSULE ORANGE P 844 dextroamphetamine saccharate amphetamine aspartate monohydrate dextroamphetamine sulfate amphetamine sulfate er capsule

CAPSULE ORANGE P 844

4 years ago CAPSULE ORANGE P 844 dextroamphetamine saccharate amphetamine aspartate monohydrate dextroamphetamine sulfate amphetamine sulfate er capsule

P 844 CAPSULE ORANGE

16 HOW SUPPLIED/STORAGE AND HANDLING Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are supplied as: 5 mg capsule: Cap: blue opaque printed ā€œPā€ in black ink and Body: white opaque printed ā€œ839ā€ in black ink NDC 49884-839-01, Bottles of 100 10 mg capsule: Cap: blue opaque printed ā€œPā€ in black ink and Body: blue opaque printed ā€œ840ā€ in black ink NDC 49884-840-01, Bottles of 100 15 mg capsule: Cap: white opaque printed ā€œPā€ in black ink and Body: blue opaque printed ā€œ841ā€ in black ink NDC 49884-841-01, Bottles of 100 20 mg capsule: Cap: orange opaque printed ā€œPā€ in black ink and Body: orange opaque printed ā€œ842ā€ in black ink NDC 49884-842-01, Bottles of 100 25 mg capsule: Cap: white opaque printed ā€œPā€ in black ink and Body: orange opaque printed ā€œ843ā€ in black ink NDC 49884-843-01, Bottles of 100 30 mg capsule: Cap: orange opaque printed ā€œPā€ in black ink and Body: white opaque printed ā€œ844ā€ in black ink NDC 49884-844-01, Bottles of 100 Dispense in a tight, light-resistant container as defined in the USP. Store at 20 ĀŗC to 25Āŗ C (68Āŗ F to 77Āŗ F); excursions permitted between 15 to 30Āŗ C (59 to 86Āŗ F) [see USP Controlled Room Temperature]. Disposal Comply with local laws and regulations on drug disposal of CNS stimulants. Dispose of remaining, unused, or expired Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release at authorized collection sites such as retail pharmacies, hospital or clinic pharmacies, and law enforcement locations. If no take-back program or authorized collector is available, mix Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release with an undesirable, nontoxic substance to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and discard Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release in the household trash.


More pills like CAPSULE P 844












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site